Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EB-203 Eye Drops in Healthy Volunteers
NCT05538949Phase 1Completed
- Sponsor
- EyebioKorea
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EB-203 in exudative macular degeneration (5 arms), sponsored by EyebioKorea. Primary endpoint: Frequency of Adverse Events (AEs) and Adverse Drug Reactions (ADR) at Day 10. Started Jun 2022; status: completed.
02
Drugs
EB-203
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05538949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538949.